Altimmune Reports 24 Week Interim Analysis Results of Pemvidutide in P-II Trial (MOMENTUM) and P-Ib Trial for Obesity and Type 2 Diabetes
Shots:
- The 48wk. P-II trial and 12wk. P-Ib trial evaluates pemvidutide vs PBO in a ratio (1:1:1:1) in 320 & 54 patients. In the (MOMENTUM) trial, pemvidutide (1.2/1.8/2.4mg) showed mean weight losses of 7.3%/9.4%/10.7% vs 1.0%; 8.2%/10.6%/11.9% vs 0.8% with baseline body weight ≤115kg
- ~50% achieved ≥10% weight loss, ~20% achieved ≥15% weight loss @24wks., robust reductions in waist circumference, serum lipids & BP without increases in heart rate, treatment discontinuation rates (24.0% vs 28.2%). The trial is expected to be completed in Q4’23 & will initiate a P-II biopsy NASH trial in mid-2023
- In the P-Ib trial, mean weight losses of 4.4%/6.1%/7.7% at 12wks. over mean weight gain of 0.8% in the PBO group with no hyperglycemic AEs & SAEs, no AEs leads to study discontinuation, glucose homeostasis was maintained with no changes in fasting glucose or HbA1c in both trials
Ref: Altimmune | Image: Altimmune
Related News:- Altimmune Reports 24-Week (12-Week Extension) Trial Results of Pemvidutide for the Treatment of Non-Alcoholic Fatty Liver Disease
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.